Bloodwork question about tirzepatide. Baseline, three years in, and the numbers moved in a direction I did not expect.
If you need three other compounds to notice the first one, you have not tested the first one.
My rule now: if a claim cannot survive being written down with the numbers attached, it is marketing.
There is a serious question about whether the studied form matches what is sold, and nobody in a thread can answer it.
Most of the popular protocols are borrowed from clinical populations and applied to healthy people without comment.
Where does the human data stop and the extrapolation start?
Read methods.
This is the kind of post the forum exists for. Three years in on tirzepatide and it lines up.
Underdosing and tolerance are indistinguishable from the inside, and everyone picks the flattering explanation.
Narrow conclusion. Currently on tirzepatide myself.